NON-HODGKIN LYMPHOMA,B CELL

This study tests a new drug, MEN1703, given alone or with another drug called glofitamab, in people with aggressive B-cell non-Hodgkin lymphoma that has come back or not responded to at least two prior treatments. About 178 adults will join to see if the treatment is safe and hel…

This early-phase study tests a new treatment called SynKIR-310 for adults with B-cell non-Hodgkin lymphoma that has come back or not responded to at least two prior therapies. The treatment uses a patient's own immune cells, modified to recognize and attack cancer cells. The main…

This study tests a new type of CAR-T cell therapy that is made from donor cells (universal) and targets CD19 on cancer cells. It is for people with relapsed or refractory B-cell non-Hodgkin lymphoma. Up to 6 adults will receive the treatment to check safety and side effects.

This study tests a new treatment called BRL-201 for people with a type of blood cancer (B-cell non-Hodgkin lymphoma) that has come back or not responded to standard therapy. The treatment uses the patient's own immune cells, which are modified in a lab to better find and attack c…

This study looks at whether CAR T cell therapy, a type of cancer treatment that uses a patient's own immune cells, can be safely given to people with moderate to severe kidney problems. About 20 adults with certain blood cancers (like lymphoma, myeloma, or leukemia) will receive …

This study is observing 130 adults with B-cell non-Hodgkin lymphoma who are scheduled to receive CAR-T cell therapy. Researchers want to see if having low muscle mass (sarcopenia) affects how well the treatment works or causes more side effects. Participants will not receive any …

This study watches 1,500 people with B-cell non-Hodgkin lymphoma who are getting new antibody treatments in Italian clinics. Researchers will track how many patients respond, how long they stay well, and what side effects occur. The goal is to see how these drugs work outside of …